These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 29763411

  • 1. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
    Nagar S, Patel J, Stanford RH.
    Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
    [Abstract] [Full Text] [Related]

  • 2. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [Abstract] [Full Text] [Related]

  • 3. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 4. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH.
    Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
    [Abstract] [Full Text] [Related]

  • 5. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr; 10():2055-66. PubMed ID: 26451101
    [Abstract] [Full Text] [Related]

  • 7. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC, Stemkowski S, Stanford RH, Tao Z.
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [Abstract] [Full Text] [Related]

  • 8. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY, Kim HI, Rhee CK, Yoo KH, Park YB, Kim Y, Lee SE, Kim JA, Hwang YI.
    Int J Chron Obstruct Pulmon Dis; 2024 Nov; 19():1661-1671. PubMed ID: 39050737
    [Abstract] [Full Text] [Related]

  • 9. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS, Landis SH, Wurst K, Le H.
    Respir Res; 2015 Nov 16; 16():141. PubMed ID: 26572740
    [Abstract] [Full Text] [Related]

  • 10. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 Nov 16; 17():1781-1795. PubMed ID: 35983168
    [Abstract] [Full Text] [Related]

  • 11. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 12. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
    Strange C, Walker V, DePietro M, Tong J, Kurlander J, Carlyle M, Millette LA, Wittbrodt E.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 16; 14():1377-1388. PubMed ID: 31303751
    [Abstract] [Full Text] [Related]

  • 13. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
    Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E.
    Int J Chron Obstruct Pulmon Dis; 2022 Nov 16; 17():1715-1733. PubMed ID: 35941901
    [Abstract] [Full Text] [Related]

  • 14. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E.
    Respir Med; 2018 Sep 16; 142():73-80. PubMed ID: 30170806
    [Abstract] [Full Text] [Related]

  • 15. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Sep 16; 18():231-245. PubMed ID: 36908830
    [Abstract] [Full Text] [Related]

  • 16. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Ann Pharmacother; 2017 Nov 16; 51(11):945-953. PubMed ID: 28677404
    [Abstract] [Full Text] [Related]

  • 17. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 16; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 18. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Aug 16; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 19. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 16; 7():201-9. PubMed ID: 22500120
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.